Pharmaceutical Inspection Machines Market

Pharmaceutical Inspection Machines Market Size, Share & Trends

The size of global pharmaceutical inspection machines market in terms of revenue was estimated to be worth $0.9 billion in 2024 and is poised to reach $1.4 billion by 2029, growing at a CAGR of 7.6% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

The major factors driving the pharmaceutical inspection machines growth are increasing use of inspection machines by pharmaceutical and biotechnology companies, increasing number of inspection checkpoint mandates in pharmaceutical products, and rise in pharmaceutical outsourcing in emerging economies. Additionally, integration of technologies such as IoT, machine learning, and artificial intelligence in pharmaceutical inspection systems, further fueling market growth.

Pharmaceutical Inspection Machines Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Global Pharmaceutical inspection machines market Dynamics

Driver: Increasing number of inspection checkpoint mandates

The increase in inspection checkpoints is driven by several key factors including regulatory compliance, good manufacturing practices, quality assurance, and advancement in technology. Regulatory compliance is critical, with stringent requirements from agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe establish and enforce strict guidelines and regulations to ensure that pharmaceutical products meet rigorous standards of safety, efficacy, and quality before they are allowed on the market. For instance, in February 2024, USD FDA increased the number of inspections at Indian drug manufacturing units amid growing concerns over the quality of drugs.Almost 200 unannounced inspections were conducted by FDA in 2023 in India following a hiatus during the pandemic. Similarly, the domestic FDA inspections related to devices rose from 382 in the year 2021 to 935 in 2022, which marks almost 144% increase.Thorough inspection protocols are essential for regulatory compliance.

Restraint: High Initial Investment

The substantial initial investment required for pharmaceutical inspection machines poses a significant challenge to market growth. These sophisticated and automated systems demand high capital expenditure for procurement, installation, and integration into existing production lines. This financial burden is particularly daunting for small and medium-sized enterprises (SMEs), which represent a large segment of the manufacturing industry. The steep costs can deter these companies from adopting essential inspection technologies, despite their crucial role in ensuring product quality and regulatory compliance. High inspection quality requires the machine to detect not only obvious defects, such as black dots and shape abnormalities, but also critical flaws that affect functionality—like lamination tendency or coating defects—and issues affecting product identification, such as the legibility of engraving or printing.

New entrants must bear huge production costs and very low margins because new facilities cannot quickly attain economies of scale. Simultaneously, they must maintain the prices according to the prevailing market trend to sustain competition. Many pharmaceutical companies are concerned about the cost implications of introducing new technologies and processes. Several pharmaceutical companies are concerned about the financial impact. It’s been observed that the average cost of a modern vision inspection system ranges between USD 5,000 to 20,000 which covers the hardware cost, software costs, computation costs, and storage costs. Similarly, the price range of vision inspection system in India ranges from USD 48.08 to USD 0.12 million

Opportunity: Advancement in technologies such as IoT, machine learning, and artificial intelligence

The pharmaceutical inspection machines market is experiencing significant growth due to the integration of innovative technologies in the inspection systems. Another significant reason that contributes in the growth of pharmaceutical inspection machines is due to increased regulatory scrutiny on the safety and quality of manufactured products and the need to prevent financial losses from product recalls or packaging issues. The focus on optimizing production and packaging processes and reducing the reliance on re-inspection or manual inspection is driving more companies to develop cost-effective automated systems.

Several companies in the market are heavily investing in R&D to expand their product portfolios and strengthen their market positions. Technological advancements over the past five years, including improvements in sensors, CPU processing speeds, camera dynamic range and resolution, real-time object detection, color information usage, point cloud analysis, machine vision cloud computing, and computational cameras, are expected to propel the vision inspection systems forward. For instance, in Apil 2024, Cognex Corporation launched world’s first In-Sight L38 3D Vision System, which combines AI, 2D, and 3D vision technologies to solve a range of inspection and measurement applications.. Similarly in April 2023, SwitchOn (India) known for AI -based vision inspection startup, raised USD 4.2 million through a funding round, led by a Singapore-based fund in order to expand rapid growth in India, scale internationally with large enterprises, make key hires in sales and technology and also invest in research and development. High-resolution cameras and advanced X-ray detectors are now capable of capturing detailed images at higher speeds, allowing for real-time inspection and immediate feedback during the manufacturing process.

Challenge: Complexities in integrating pharmaceutical inspection machines

Inspections remain an indispensable tool of modern manufacturing to prevent equipment failures, process deviations, and quality defects. Its integration into existing manufacturing processes presents several intricate challenges that demand careful management to ensure smooth operations and enhanced productivity. There is a significant need to simplify the integration process for the different components of pharmaceutical inspection machines and the production line at the application site. For instance, the assembly instructions for the integration of machines are often significantly outdated and seldom reflect active quality alerts or engineering change orders

Ecosystem Analysis Pharmaceutical Inspection Machines Market

The inspection systems segment dominated the pharmaceutical inspection machines industry in 2023.

Based on component, the pharmaceutical inspection machines market is segmented into into inspection systems and software. The inspection systems segment is further bifurcated into vision inspection systems, X-ray inspection systems, leak detection systems, metal detectors, combination systems, checkweighers, and other inspection systems. The inspection systems segment dominated the market owing to factors such as increasing emphasis on product quality and safety, advancements in technology such as machine vision, rise in pharmaceutical production globally, adoption of automation to improve efficiency and reduce operational costs and need for efficient and reliable inspection processes to detect defects, contaminants, and ensure proper labelling.

The pharmaceutical companies is poised to exhibit substantial growth in the global pharmaceutical inspection machines industry at a significant CAGR throughout the forecast period.

Based on end user, the pharmaceutical inspection machines market is segmented into pharmaceutical companies, biotechnology companies and CROs & CDMOs. In 2023, pharmaceutical companies segment accounted for a largest share of the end user segment. Advancements in manufacturing technologies such as automation and robotics, stringent regulatory requirements for high-quality production, complexity of drug formulations and packaging and rising focus by pharmaceutical companies on innovation and expansion into new therapeutic areas and markets.

North America dominated global pharmaceutical inspection machines industry in 2023.

By region, pharmaceutical inspection machines market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. In 2023, North America dominated the pharmaceutical inspection machines market followed by Europe. North America's dominance in the pharmaceutical inspection machines market is attributed to significant investment in research and development, high adoption of advanced technologies and presence of large number of pharmaceutical, biotechnology companies in the region.

Asia Pacific region is likely to grow at highest CAGR during the forecast period of 2024-2029. Asia Pacific's growth in the pharmaceutical inspection machines market is propelled by expanding pharmaceutical manufacturing capabilities and the rise in pharmaceutical outsourcing. Furthermore, presence of key market players in the region is likely to spur the market growth.

Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Key players in the pharmaceutical inspection machines market include Körber AG (Germany), Mettler-Toledo (Switzerland), Omron Corporation (Japan), Cognex corporation (US), Stevanato Group (Italy), Antares Vision S.P.A (Italy), Syntegon Technology GmbH (Germany), Optel Group (Canada), Jekson Vision (India), ACG (India), Brevetti CEA SPA (Italy), Roquette Frères (France), Tofflon Life Science (China), Proditec (France), Wipotec Gmbh (Germany) and CMP Pharma S.R.L (Italy) among others.

Scope of the Pharmaceutical Inspection Machines Industry

This report categorizes the pharmaceutical inspection machines market to forecast revenue and analyze trends in each of the following submarkets:

By Component

• Inspection Systems
  • Vision Inspection Systems
    • Multifunctional Vision Systems
    • Specialized Vision Systems
  • Leak Detection Systems
  • X-Ray Inspection Systems
  • Combination Systems
  • Checkweighers
  • Metal Detectors
  • Other Inspection Systems
• Software

By Type

• Fully Automated Inspection Machines
• Semi-Automated Inspection Machines
• Manual Inspection Machines Antibodies

By Packaging Type

• Ampoules & Vials
• Syringes
• Blister
• Bottles
• Other Packaging Type

By Formulation

• Oral
  • Tablets & Capsules
  • Oral Solution and suspensions/syrups
  • Other Oral formulation
• Parenteral
• Other Formulation

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• CROs & CDMOs

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • Rest of Middle East &AFrica

Recent Developments of Pharmaceutical Inspection Machines Industry:

• In April 2024, Cognex Corporation (US) launched its first AIN powered 3D vision system in order to solve a range of inspection and measurement applications.
• In December 2023, Körber AG (Germany) and Franz Ziel GmbH (Germany)  entered into a partnership agreement in order to acquire Franz Ziel's share for expanding its market expertise in the field of cleanroom technology for the pharmaceutical and biotech industries as Framz Ziel solutions seamlessly complement Körber's offerings in inspection and packaging solutions
• In August 2023, Cognex Corporation (US) acquired Moritex Corporation (Japan), a renowned company in Machine Vision Optics components and advanced imaging solutions through an investment of over USD 275 million in order to deepen Cognex’s machine vision system in Japan.
• In February 2023, Antares Vision (Italy) and PYGSA Sistemas Y Applicaciones SL (Spain) entered into binding agreement under which Antares Vision acquired 30% stakes of PYGSA for expanding its distribution of its solutions in Spain, in all relevant sectors (Life Science, Cosmetics, Food & Beverage) and in Portugal for Food & Beverage only

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst